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Abstract
Data are sparse on Mycobacterium tuberculosis infection among patients with cancer in Egypt. We sought to detect the presence of tuber-
culosis (TB) disease among patients with malignant conditions and suspected TB and to study the main risk factors. Also, we compared
different diagnostic procedures and detected the antimicrobial susceptibility of M. tuberculosis isolates against rifampin and isoniazid. One
hundred patients were included in this study, all of them had malignant conditions and were suspected by the clinicians of having TB.
Identiﬁcation of M. tuberculosis in different specimens was performed by smear microscopy, followed by Lowenstein–Jensen medium and
Mycobacterium growth indicator tube (MGIT) cultures and artus real-time PCR. In addition, an indirect MGIT anti-TB susceptibility test
was carried out against rifampin and isoniazid. A total of 76% of studied cases were found to be TB positive. The frequencies of TB-posi-
tive cases in the bronchogenic, haematological and solid tumour malignancy groups were 21%, 25% and 30%, respectively. Signiﬁcant dif-
ferences between pulmonary and extrapulmonary TB in different malignancy groups were recorded. Real-time PCR showed the highest
overall diagnostic efﬁciency. Multidrug-resistance of M. tuberculosis to both rifampin and isoniazid was detected in 28.6% of examined iso-
lates. Infection in cancer patients with TB was signiﬁcantly more often recorded among elderly patients and those suffering from poverty.
Pulmonary TB is more common than extrapulmonary TB in patients with malignancy. Real-time PCR is the most accurate and rapid
method for TB diagnosis. MGIT-rifampin resistance may be used as a reliable marker for detection of multidrug-resistant TB. Diagnosis
and instituting treatment course for active or latent TB infection are crucial before starting anticancer therapy.
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Abstract
Four non-repetitive, clonally related (ST114), carbapenem-resistant Acinetobacter baumannii strains isolated in the USA were examined
to understand the mechanisms of carbapenem resistance including screening for the presence of an insertion sequence upstream of the
blaOXA-51-like gene, which could be involved in the control and expression of the antibiotic-resistance gene. We observed that the main
mechanisms of carbapenem resistance were the result of the over-expression of the blaOXA-58-like and the blaOXA-65 gene, both of which
had the presence of ISAba825 upstream of the genes. The importance of this element was shown by isolating plasmid-cured isogenic
strains that had lost the plasmid with the ISAba825-blaOXA-58-like genes but during that same process also lost the chromosomal
ISAba825 element present upstream of the blaOXA-65 gene. A 16-fold decrease in minimum inhibitory concentration of imipenem and an
eight-fold decrease in the minimum inhibitory concentration of meropenem were seen in the isogenic strains that lost the plasmid. The
study presents the ﬁrst report of ISAba825 simultaneously governing the blaOXA-65 gene and the blaOXA-58-like gene expression and also
highlights the importance of this element in carbapenem-sensitive isogenic strains, which were once carbapenem resistant.
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Abstract
EUCAST breakpoint criteria are being adopted by automatic antimicrobial susceptibility testing systems. The accuracy of the Phoenix
Automated System in combination with 2012 EUCAST breakpoints against recent clinical isolates was evaluated. A total of 697 isolates
(349 Enterobacteriaceae, 113 Pseudomonas spp., 25 Acinetobacter baumannii, 11 Stenotrophomonas maltophilia, 95 Staphylococcus aureus, 6
coagulase negative staphylococci, 77 enterococci and 21 Streptococcus pneumoniae) with deﬁned resistance phenotypes and well-charac-
terized resistance mechanisms recovered in Spain (n = 343) and Italy (n = 354) were tested. Comparator antimicrobial susceptibility
testing data were obtained following CLSI guidelines. Experimental agreement (EA), deﬁned as MIC agreement ±1 log2 dilution, category
agreement (CA) and relative discrepancies (minor (mD), major (MD) and very major discrepancies (VMD)) were determined. The over-
all EA and CA for all organism-antimicrobial agent combinations (n = 6.294) were 97.3% and 95.2%, respectively. mD, MD and VMD
were 4.7%, 1.3% and 2.7%, all of them in agreement with the ISO (ISO20776-2:2007) acceptance criteria for assessment of susceptibility
testing devices. VMD were mainly observed in amoxicillin-clavulanate and cefuroxime in Enterobacteriaceae and gentamicin in Pseudomo-
nas aeruginosa, whereas MD were mainly observed in amoxicillin-clavulante in Enterobacteriaceae. mD were mainly observed in Entero-
bacteriaceae but distributed in different antimicrobials. For S. aureus and enterococci relative discrepancies were low. The Phoenix
system showed accuracy assessment in accordance with the ISO standards when using EUCAST breakpoints. Inclusion of EUCAST cri-
teria in automatic antimicrobial susceptibility testing systems will facilitate the implementation of EUCAST breakpoints in clinical micro-
biology laboratories.
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Abstract
There are only sparse data on the short-term and medium-term clinical impacts of Campylobacter concisus infection. A clinical study was
performed during a 2-year period to determine the clinical manifestations in C. concisus-positive adult patients. A case patient was
deﬁned as an adult patient (‡18 years) with a C. concisus-positive stool sample during the study period. Clinical data were obtained with
use of a questionnaire supplemented with the patients’ medical records, if any. The short-term and medium-term clinical manifestations
in these patients were compared with those of patients with Campylobacter jejuni/Campylobacter coli infection. One hundred and seventy-
four C. concisus patients and 196 C. jejuni/C. coli patients participated in the study. Patients with pre-existing inﬂammatory bowel disease
or microscopic colitis or enteric co-infection were excluded from review of the clinical manifestations. Comparison of the short-term
clinical manifestations in 139 C. concisus patients with those in 187 C. jejuni/C. coli patients showed a signiﬁcantly lower prevalence of
fever, chills, mucus and blood in stools, and weight loss. However, 80% of C. concisus patients, but only 32% of C. jejuni/C. coli patients,
had diarrhoea for >2 weeks. After a 6-month follow-up period, 12% of C. concisus patients were diagnosed with microscopic colitis,
whereas no C. jejuni/C. coli patients were diagnosed with non-infective colitis. Irritable bowel symptoms were common in both groups at
follow-up. C. concisus infection seems to cause a milder course of acute gastroenteritis than C. jejuni/C. coli infection, but is associated
with more prolonged diarrhoea.
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Abstract
Dutch laboratories are currently changing their breakpoint criteria from mostly Clinical Laboratory and Standards Institute (CLSI)
breakpoints to European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints. To evaluate the impact of these
changes, we studied antimicrobial resistance trends of Escherichia coli in blood specimens from January 2008 to January 2012 using CLSI
and EUCAST breakpoints and compared them with the antimicrobial susceptibility test (AST) interpretations reported by Dutch labora-
tories participating in the Infectious Disease Surveillance Information System for Antibiotic Resistance (ISIS-AR). ISIS-AR collects AST
interpretations, including underlying minimal inhibitory concentrations (MICs) of routinely cultured bacterial species on a monthly basis
from Dutch laboratories. MICs of Etests or automated systems were reinterpreted according to the CLSI 2009 and EUCAST 2010
guidelines. Trends in non-susceptibility (i.e. intermediate resistant and resistant) over time were analysed by the Cochran–Armitage test
for trend. The effects of the change from CLSI to EUCAST breakpoints on non-susceptibility were small. There were no differences in
non-susceptibility to amoxicillin, amoxicillin/clavulanic acid, cefuroxim, gentamicin and co-trimoxazol and only small differences (1–1.5%)
for ciproﬂoxacin between AST interpretations by CLSI or EUCAST. However, for ceftazidime, and cefotaxime/ceftriaxone the propor-
tion of non-susceptibility was substantially higher when EUCAST breakpoints were used (2–3%). The effects on time trends of the
change in guidelines were limited, with only substantial differences for the oxymino-cephalosporins. Our study shows that the imple-
mentation of EUCAST breakpoints has a limited effect on the proportion of non-susceptible isolates and time trends in E. coli for most,
but not all, antimicrobial agents.
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Abstract
Mycobacterium tuberculosis m-RNA quantitation in sputum of pulmonary tuberculosis patients before starting supervised treatment was
evaluated as a surrogate for response. Sputum specimens were collected from 50 patients (DOTS category II treatment; 303 specimens,
day 0 to fourth month) and 16 controls (non-tubercular lung disorders). Microscopy, reverse-transcriptase PCR and DNA-PCR were
compared with culture using the BACTEC 460 system. TaqMan real-time RT-PCR quantitated the mRNA levels. RT-PCR (sensitivity, 10
organisms/mL) and culture results were concordant. mRNA declined with time and correlated with culture clearance. Thirty-nine (78%)
patients were smear, culture and RT-PCR negative at 2 months of treatment. Day 0 mRNA levels had statistically signiﬁcant correlation
with time to culture conversion and drug resistance (p 0.041). Of seven patients with sensitive isolates but high m-RNA levels, four pre-
sented with re-infection/mixed infection later, while three presented with relapse (ninth to twentieth month). The control group speci-
mens were negative for the above tests. M. tuberculosis mRNA in the sputum is a useful prognostic marker and its quantitation an early
and reliable indicator for monitoring response, prediction of culture conversion, drug resistance, re-infection and relapse. mRNA quanti-
tation may prove to be of great value for evaluating the response to new drugs under trial.
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